Insmed’s BRINSUPRI (brensocatib) has achieved a significant regulatory milestone, becoming the first FDA-approved therapy for non-cystic fibrosis bronchiectasis (NCFB) as well as the first approved DPP1 inhibitor. As the only NCFB treatment, this marks not just a scientific breakthrough but also a transformation in a market historically characterized by significant unmet needs. BRINSUPRI represents a novel class of medication that directly targets neutrophilic inflammation and the underlying causes of bronchiectasis exacerbations, providing a new therapeutic approach for patients.
In the US, approximately 390,000 individuals were diagnosed with NCFB in 2024, with g...
